MWAM
MRNA icon

Manhattan West Asset Management’s Moderna MRNA Stock Holding History

Manhattan West Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,712
Closed -$1.75M – 144
2024
Q2 		$1.75M Sell
14,712
-1,160
-7% -$147K 0.47% 65
2024
Q1 		$1.69M Buy
15,872
+1,214
+8% +$122K 0.41% 66
2023
Q4 		$1.46M Sell
14,658
-2,690
-16% -$226K 0.41% 69
2023
Q3 		$1.36M Buy
17,348
+5,373
+45% +$599K 0.42% 61
2023
Q2 		$1.45M Buy
11,975
+6,455
+117% +$861K 0.54% 56
2023
Q1 		$848K Buy
5,520
+320
+6% +$52.8K 0.37% 73
2022
Q4 		$934K Buy
5,200
+152
+3% +$24.9K 0.48% 65
2022
Q3 		$597K Buy
5,048
+493
+11% +$74.8K 0.37% 71
2022
Q2 		$651K Buy
4,555
+737
+19% +$105K 0.39% 69
2022
Q1 		$658K Buy
+3,818
New +$643K 0.36% 66

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Manhattan West Asset Management's MRNA Position: Q3 2024 in Review

Manhattan West Asset Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 14,712 shares — an estimated $1.75M sold.

Manhattan West Asset Management first reported a position in MRNA in Q1 2022 and held it in 10 quarters. The position peaked at $1.75M in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Manhattan West Asset Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Manhattan West Asset Management sold 14,712 Moderna shares in Q3 2024, an estimated $1.75M.
  • Manhattan West Asset Management first reported a position in Moderna in Q1 2022 and held it in 10 quarters.
  • Manhattan West Asset Management's Moderna position peaked at $1.75M in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Manhattan West Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.